KEY DEFINITIONS 6.2.1. Baseline Values The baseline value of a measurement is the value of the last available assessment take n before administration of the first dose of SL-701. 6.2.2. First/Last Dose Dates and Study Day The date of first dose of study drug is defined as the date of the fir st injection of SL-701. This definition applies to all analysis sets and whether or not the first injection w ith SL-701 was part of a complete treatment that was administered. In Stages 1 and 2, the date of the last dose of study drug is defined as the da te of the last treatment with any component of the treatment regimen. Study day is defined as the number of days from the date of first dose of SL-701to the event/visit date. For dates equal to or later than the first dose of study drug, study day is calculated as fol lows: Study Day = Event or Visit Date – First Dose Date + 1 Consequently, the day immediately prior to the first dose date is assigned as Day 0. The study day of the first dose of study drug is assigned as Day 1. One (1) month will be considered to be equal to 30.4375 days when calculating durations or survival times in months. For analyses based on discrete time points, a measurement t aken ±15.21875 days from the exact specific time point (calculated as [observation day-day 1]/30.4375) will be considered as the value for the analysis. For the purpose of survival anal ysis, survival status obtained between days 350-380 will be considered the 12th-month assessment. For the purpose of PFS-6 and PFS-12 calculation, PFS status obtained between days 167-198 will be considered the 6th-month assessment and status obtained between days 350-380 will be considered the 12th month. The table below defines the day intervals for a 12-month period. Month Days Interval 1 15-46 2 ≥46-76 3 ≥76-107 4 ≥107 -137 5 ≥137 -167 6 ≥167 -198 7 ≥198 -228 8 ≥228 -259 9 ≥259 -289 10 ≥289 -320 11 ≥320 -350 12 ≥350 -380 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 24 of 63 6.3. MISSING DATA The method for imputing partial dates for the assignment of treatment-emergent sta tus for AEs is described in Section 11.3 of this SAP, as are the methods for assignment of m issing AE severities and missing causal relationships to study drug. The method for imputing partial dates for the assignment of prior or concomitan t medication status is described in Section 7.5.1 of this SAP. The methods for imputing vital status when estimating OS-12,PFS-6 and PFS-12 using a one- sample binomial proportion are described in Section 8.1 and 8.3 of this SAP, respectively. No other efficacy or safety data will be imputed.